Social media

What does successful biomarker integration look like in early-phase CNS trials? Discover how leading researchers are applying imaging, wet, genetic, and digital biomarkers to enrich populations and improve decision-maki...

One billion people worldwide will be living with obesity by 2030. Connect with us at Obesity Week, booth #520 on Nov 4–7 to learn how ICON supports obesity trials with market intelligence, regulatory expertise, and ready...

Meet ICON at #ObesityWeek, Nov 4–7 at booth \#520 to arrange time with our experts and explore how we support next-gen obesity trials. From proof of concept to large portfolios, ICON delivers market intelligence and read...

ICON invites you to attend a presentation by Arjen Akkerman, Senior Director, Accelerated Pharmaceutical Solutions on 28 October at 11:35 am at Messe Frankfurt. In his session, “From collaboration to commitment: Strengt...

ICON invites you to attend a presentation by Arjen Akkerman, Senior Director, Accelerated Pharmaceutical Solutions on 28 October at 11:35 am at Messe Frankfurt. In his session, “From collaboration to commitment: Strengt...

This October, ICON will be in Copenhagen as a proud sponsor of the #OCTNordics conference, taking place on the 21st and 22nd. We invite you to stop by booth #41 to meet our team and discover how ICON is partnering with ...

This October, ICON will be in Copenhagen as a proud sponsor of the #OCTNordics conference, taking place on the 21st and 22nd. We invite you to stop by booth \#41 to meet our team and discover how ICON is partnering with...

Meet ICON’s experts at #ESMO25, booth #3034 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https:...

Meet ICON’s experts at #ESMO25, booth \#3034 to discuss how our extensive testing capabilities, clinical research experience and scientific expertise can support global oncology and haematology research programmes. https...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

In today’s data-rich healthcare landscape, life sciences leaders no longer need to choose between open or closed claims. Integration is the key to unlocking complete, representative, and actionable insights across payer,...